Stock HYL HYLORIS PHARMACEUTICALS SA
Add to a list
To use this feature you must be a member
Log inSign up

News Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Market Closed - Euronext Bruxelles
Other stock markets
 11:35:16 2024-04-22 am EDT 		5-day change 1st Jan Change
11.95 EUR -0.42% Intraday chart for Hyloris Pharmaceuticals SA -2.85% -6.27%
Mar. 14 Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 CI
Mar. 14 Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024
CI
Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
GL
Communication at the request of the FSMA on the transactions with Qliniq
GL
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Communication at the request of the FSMA on the transactions with Qliniq
AQ
Hyloris to Report 2023 Full-Year Results on 14 March 2024
GL
Hyloris to Report 2023 Full-Year Results on 14 March 2024
AQ
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada
MT
Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada
GL
Hyloris Starts Patient Recruitment in Late-stage Trial for Proprietary Oral Rinse
MT
Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
GL
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%
MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US
MT
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)
GL
Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis
CI
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication
MT
Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)
GL
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HYL Stock
  4. News Hyloris Pharmaceuticals SA